- Home
- ESEA vs DRUG Comparison
ESEA vs DRUG Comparison
Compare ESEA & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESEA
- DRUG
- Stock Information
- Founded
- ESEA 2005
- DRUG 2019
- Country
- ESEA Greece
- DRUG United States
- Employees
- ESEA N/A
- DRUG N/A
- Industry
- ESEA Marine Transportation
- DRUG Pharmaceuticals and Biotechnology
- Sector
- ESEA Consumer Discretionary
- DRUG Health Care
- Exchange
- ESEA Nasdaq
- DRUG Nasdaq
- Market Cap
- ESEA 235.7M
- DRUG 253.2M
- IPO Year
- ESEA 2006
- DRUG N/A
- Fundamental
- Price
- ESEA $30.48
- DRUG $36.20
- Analyst Decision
- ESEA Buy
- DRUG Strong Buy
- Analyst Count
- ESEA 1
- DRUG 4
- Target Price
- ESEA $53.00
- DRUG $84.33
- AVG Volume (30 Days)
- ESEA 38.5K
- DRUG 37.1K
- Earning Date
- ESEA 05-22-2025
- DRUG 05-16-2025
- Dividend Yield
- ESEA 8.48%
- DRUG N/A
- EPS Growth
- ESEA N/A
- DRUG N/A
- EPS
- ESEA 16.20
- DRUG N/A
- Revenue
- ESEA $212,897,313.00
- DRUG N/A
- Revenue This Year
- ESEA $4.65
- DRUG N/A
- Revenue Next Year
- ESEA $4.36
- DRUG N/A
- P/E Ratio
- ESEA $1.90
- DRUG N/A
- Revenue Growth
- ESEA 12.43
- DRUG N/A
- 52 Week Low
- ESEA $28.36
- DRUG $0.93
- 52 Week High
- ESEA $50.92
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- ESEA 40.78
- DRUG 51.38
- Support Level
- ESEA $30.60
- DRUG $35.35
- Resistance Level
- ESEA $31.85
- DRUG $37.90
- Average True Range (ATR)
- ESEA 1.11
- DRUG 2.17
- MACD
- ESEA -0.13
- DRUG 0.24
- Stochastic Oscillator
- ESEA 35.42
- DRUG 68.33
About ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.